Python cardiomyocyte

Python hearts reveal mechanisms relevant to human heart health and disease

March 5, 2019

Burmese pythons have an amazing response to fasting and feeding. They can go without eating for months, and when they do eat, they can consume twice their body mass or more. Their hearts then nearly double in size in response to such a feeding, and after digestion most of that...


American Heart Association recognizes distinguished professor’s work

Nov. 10, 2017

Leslie Leinwand has won the American Heart Association's 2017 Distinguished Scientist award for outstanding contributions to the field of heart health The usage of fats from python hearts on mammals and the cardiovascular differences between females and males are at the core of research by a University of Colorado Boulder...


Leinwand joins American Academy of Arts and Sciences

April 24, 2014

University of Colorado Boulder biologist Leslie Leinwand has been selected as a member of the 2014 class of the American Academy of Arts and Sciences, which honors the leading “thinkers and doers” from each generation, including scientists, scholars, writers and artists. Leinwand—chief scientific officer for CU-Boulder’s BioFrontiers Institute and a...

Leslie Talks with Students

Stopping heart disease before it starts

Feb. 28, 2014

The motor protein, myosin, has fascinated BioFrontiers Chief Scientific Officer Leslie Leinwand for more than 25 years. This protein is responsible for making muscles contract in the body, but Leinwand, a professor in molecular, cellular and developmental biology, is interested in its function in one important muscle: the heart. Myosin...

Cardiac Cells

BioFrontiers Scientist Tackles a Childhood Disease of the Heart

Feb. 27, 2013

BioFrontiers Chief Scientific Officer Leslie Leinwand, has been studying the motor protein, myosin, for 25 years. This important protein is responsible for making muscles contract, including one vital muscle: your heart. Myosin drives heart muscle contraction, and when this protein is mutated, it has devastating effects on the cardiovascular system...


CU professor co-founds new company to develop genetic heart disease treatment

Feb. 5, 2013

A new biomedical company involving the University of Colorado Boulder, Stanford University and the Harvard Medical School has been launched with $38 million in financing from Third Rock Ventures LLC headquartered in Boston and San Francisco to develop therapeutic treatments for genetic heart diseases. The company, MyoKardia Inc. , is...

BioFrontiers researchers uncover new target for cancer research

Oct. 24, 2012

In a new paper released today in Nature , BioFrontiers Institute scientists at the University of Colorado in Boulder, T om Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA. Researchers in the two scientists’ laboratories collaborated to...

Hubert Yin

BioFrontiers faculty receive commercialization grants from the State of Colorado

June 7, 2012

Ten CU research projects were recently selected to receive grants through Colorado’s Bioscience Discovery Evaluation Grant Program (BDEG-Co). The State of Colorado Office of Economic Development and International Trade began the BDEG program in 2007, providing proof-of-concept grants to move promising CU biotechnologies closer to market readiness, as well as...